CareDx Acquires Naveris to Expand Oncology Diagnostics Portfolio
Event summary
- CareDx has agreed to acquire Naveris, a commercial-stage precision oncology diagnostics company, for $160 million upfront with up to $100 million in milestone payments.
- Naveris reported $34 million in unaudited revenue for 2025, projecting 30-40% annual growth.
- The acquisition is expected to close in the third quarter of 2026 and is not anticipated to impact CareDx’s 2026 AEBITDA guidance.
- Naveris’ TTMV® platform measures viral DNA fragments for HPV-driven cancer surveillance and has received Medicare coverage since 2023.
The big picture
CareDx’s acquisition of Naveris represents a strategic move to expand its precision medicine offerings into the rapidly growing oncology diagnostics market. The $260 million deal underscores the increasing demand for liquid biopsy solutions for cancer surveillance and MRD detection, a trend fueled by advancements in molecular diagnostics and a shift towards personalized cancer care. The acquisition allows CareDx to leverage Naveris’ established platform and Medicare coverage to accelerate growth within a concentrated specialty market.
What we're watching
- Integration Risk
- Successfully integrating Naveris’ operations and technology into CareDx’s existing infrastructure will be crucial to realizing the anticipated synergies and avoiding operational disruptions.
- Reimbursement
- Continued favorable reimbursement coverage for Naveris’ test from Medicare and other payers will be essential for driving adoption and revenue growth.
- Market Adoption
- The pace at which Naveris’ TTMV® platform gains broader adoption within the oncology market, beyond Head & Neck and Anal cancers, will determine the ultimate success of the acquisition.
Related topics